Agios Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts. The company focuses on discovering and developing innovative therapies for rare, genetically defined metabolic diseases, particularly in the field of classical hematology. Its lead product, mitapivat (marketed as PYRUKYND and AQVESME), is an approved oral therapy for adults with pyruvate kinase (PK) deficiency and thalassemia.
One customer accounted for 89% of Agios's consolidated revenue for the year ended December 31, 2025 (95% in 2024 and 96% in 2023), reflecting distribution of PYRUKYND through a concentrated specialty-pharmacy/distributor channel.